Apollomics Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
15
- Stock Symbol
-
APLM
- Investments
-
1
- Share Price
-
$17.68
- (As of Friday Closing)
Apollomics General Information
Description
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
Contact Information
Website
www.apollomicsinc.comCorporate Office
- 989 East Hillsdale Boulevard
- Suite 220
- Foster City, CA 94404
- United States
Corporate Office
- 989 East Hillsdale Boulevard
- Suite 220
- Foster City, CA 94404
- United States
Apollomics Timeline
Apollomics Stock Performance
As of 13-Nov-2026, Apollomics’s stock price is $17.68. Its current market cap is $51.5M with 2.91M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $17.68 | $17.30 | $12.58 - $28.29 | $51.5M | 2.91M | 13.5K | -$0.24 |
Apollomics Financials Summary
As of 30-Jun-2026, Apollomics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 43,396 | 38,720 | (10,455) | 34,412 |
| Revenue | 0 | 8,500 | 0 | 0 |
| EBITDA | (7,003) | (10,768) | (53,539) | (172,525) |
| Net Income | (7,177) | (10,939) | (53,858) | (172,601) |
| Total Assets | 2,214 | 6,714 | 13,098 | 55,387 |
| Total Debt | 2,199 | 643 | 966 | 4,661 |
Apollomics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Apollomics Comparisons
Industry
Financing
Details
Apollomics Competitors (45)
One of Apollomics’s 45 competitors is AnaptysBio, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AnaptysBio | Formerly VC-backed | San Diego, CA | ||||
| Mersana Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Altimmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Capricor Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Apexian Pharmaceuticals | Venture Capital-Backed | Indianapolis, IN |
Apollomics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Apollomics Patents
Apollomics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4633630-A1 | Treatment of cancer resistant to egfr tki using c-met inhibitor | Pending | 15-Dec-2022 | ||
| US-20220348674-A1 | Novel anti-cd40 antibodies | Inactive | 30-Apr-2021 | ||
| EP-4326270-A4 | Diagnostic and treatment of cancer using c-met inhibitor | Inactive | 21-Apr-2021 | ||
| US-20240218453-A1 | Diagnostic and treatment of cancer using c-met inhibitor | Pending | 21-Apr-2021 | ||
| US-20230338294-A1 | Novel pharmaceutical formulation for c-met inhibitor | Inactive | 26-Apr-2020 | A61K9/2054 |
Apollomics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Apollomics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Apollomics Acquisitions (1)
Apollomics’s most recent deal was a Merger/Acquisition with Maxpro Ventures. The deal was made on 29-Mar-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Maxpro Ventures | 29-Mar-2023 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) |
Apollomics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Apollomics FAQs
-
When was Apollomics founded?
Apollomics was founded in 2015.
-
Where is Apollomics headquartered?
Apollomics is headquartered in Foster City, CA.
-
What is the size of Apollomics?
Apollomics has 15 total employees.
-
What industry is Apollomics in?
Apollomics’s primary industry is Drug Discovery.
-
Is Apollomics a private or public company?
Apollomics is a Public company.
-
What is Apollomics’s stock symbol?
The ticker symbol for Apollomics is APLM.
-
What is the current stock price of Apollomics?
As of 13-Nov-2026 the stock price of Apollomics is $17.68.
-
What is the current market cap of Apollomics?
The current market capitalization of Apollomics is $51.5M.
-
Who are Apollomics’s competitors?
AnaptysBio, Mersana Therapeutics, Altimmune, Capricor Therapeutics, and Apexian Pharmaceuticals are some of the 45 competitors of Apollomics.
-
What is Apollomics’s annual earnings per share (EPS)?
Apollomics’s EPS for 12 months was -$0.24.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
